[go: up one dir, main page]

BR9711692A - Regulated steel promoter - Google Patents

Regulated steel promoter

Info

Publication number
BR9711692A
BR9711692A BR9711692-0A BR9711692A BR9711692A BR 9711692 A BR9711692 A BR 9711692A BR 9711692 A BR9711692 A BR 9711692A BR 9711692 A BR9711692 A BR 9711692A
Authority
BR
Brazil
Prior art keywords
promoter
regulated
iron
regulated steel
sequence
Prior art date
Application number
BR9711692-0A
Other languages
Portuguese (pt)
Inventor
Himanshu Brahmbhatt
David Emery
Adam Burn
Original Assignee
Commw Scient Ind Res Org
Australian Wool Res And Promot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO2164A external-priority patent/AUPO216496A0/en
Priority claimed from AUPO2454A external-priority patent/AUPO245496A0/en
Priority claimed from AUPO7801A external-priority patent/AUPO780197A0/en
Application filed by Commw Scient Ind Res Org, Australian Wool Res And Promot filed Critical Commw Scient Ind Res Org
Publication of BR9711692A publication Critical patent/BR9711692A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

<B>PROMOTOR REGULADO POR FERRO E USOS DO MESMO<D> A presente invenção fornece um promotor regulado por ferro. O promotor compreende a seq³ência de DNA (Figura 1), ou um fragmento da mesma que inclui a seq³ência dos resíduos 284 a 409, ou uma seq³ência de ácido nucleico funcionalmente equivalente. São também fornecidos vetores e células hospedeiras recombinantes incluindo o promotor e composições para uso na indução de uma resposta imune em um animal.<B> IRON-REGULATED PROMOTER AND USES OF THE SAME <D> The present invention provides an iron-regulated promoter. The promoter comprises the DNA sequence (Figure 1), or a fragment thereof that includes the sequence of residues 284 to 409, or a functionally equivalent nucleic acid sequence. Recombinant host vectors and cells including the promoter and compositions for use in inducing an immune response in an animal are also provided.

BR9711692-0A 1996-09-06 1997-08-08 Regulated steel promoter BR9711692A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPO2164A AUPO216496A0 (en) 1996-09-06 1996-09-06 Inducible promoters
AUPO2454A AUPO245496A0 (en) 1996-09-19 1996-09-19 Site-specific chromosomal integration system
AUPO7801A AUPO780197A0 (en) 1997-07-09 1997-07-09 Site-specific chromosomal integration system incorporating inducible promoter
PCT/AU1997/000503 WO1998010064A1 (en) 1996-09-06 1997-08-08 Iron regulated promoter and uses thereof

Publications (1)

Publication Number Publication Date
BR9711692A true BR9711692A (en) 2000-10-24

Family

ID=27157946

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9711692-0A BR9711692A (en) 1996-09-06 1997-08-08 Regulated steel promoter

Country Status (7)

Country Link
EP (1) EP0964924A4 (en)
AR (1) AR008171A1 (en)
BR (1) BR9711692A (en)
CA (1) CA2265883A1 (en)
NZ (1) NZ334649A (en)
UY (1) UY24698A1 (en)
WO (1) WO1998010064A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563311B1 (en) * 1990-12-18 2000-03-15 The General Hospital Corporation Improved vaccines
EP0692031B1 (en) * 1993-02-22 2007-04-11 The General Hospital Corporation Heterologous antigens in live cell vaccine strains

Also Published As

Publication number Publication date
WO1998010064A1 (en) 1998-03-12
UY24698A1 (en) 1998-02-12
EP0964924A4 (en) 2001-04-18
AR008171A1 (en) 1999-12-09
NZ334649A (en) 2000-08-25
CA2265883A1 (en) 1998-03-12
EP0964924A1 (en) 1999-12-22

Similar Documents

Publication Publication Date Title
RU95115239A (en) Erythropoietin analog
BR9809445A (en) Polypeptide comprising an immunogenic portion of a m antigen. tubercolosis, dna molecule, expression vector, host cell, pharmaceutical composition, vaccine, fusion protein, processes for inducing protective immunity in a patient, tuberculosis detection process in a patient, and, diagnostic kit.
BR9711123A (en) Leukotoxin-gnrh chimeras
ES2070866T3 (en) RECOMBINANT VACCINES AGAINST COCCIDIOSIS.
ES2150496T3 (en) CONDENSED CYCLLOALKYLIMIDAZOPYRIDIDS.
NO952744D0 (en) Cytokine-limiting agents
FI943512A0 (en) Human serum albumin, preparation and use
PT100344A (en) GLITARY MITOGENIC POLYPEPTIDIC FACTORS, AND ITS PREPARATION PROCESS, MITOGENIC ACTIVITY TEST, DNA SEQUENCES THAT CODE THE FACTORS AND CONSTRUCTIONS OF DNA THAT UNDERSTAND IT, HOST CELLS, PHARMACEUTICAL OR VETERINARY FORMULATIONS, USE OF POLIPEPTIDES, ANTIBODY, AND GENETIC SEQUENCE ENCODING ACTIVITY GLITARY CELL MITOGENICS.
DK1025237T3 (en) Human checkpoint kinase, hCDS1, preparations and methods
BR9811592A (en) Cytokinin oxidase
FI920760A7 (en) in vitro packaging system for cloning 95 kb DNA fragments
BR9803960A (en) D-sorbitol dehydrogenase gene.
DK525384D0 (en) FACTOR PREPARATION VIII FOR THE TREATMENT OF HAEMOFILI A INHIBITOR PATIENTS AND PROCEDURE FOR THE PREPARATION OF SUCH A PREPARATION
ATE121754T1 (en) VACCINE AGAINST BORDETELLA.
PT84089A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
HUT68379A (en) Method for modifying the cell, tissue or host tropism of a recombinant microorganism obtained this way and use thereof in medicine and veterinary medicine
ES2080060T3 (en) PROTEINS THAT HAVE ACTIVITY FROM UNION TO INTERFERON-GAMMA.
DE59712235D1 (en) IMMUNOLOGICALLY ACTIVE PROTEINS OF BORRELIA BURGDORFERI, CODING NUCLEIC ACIDS, AND THEIR USE IN TEST KITS AND AS VACCINES
MY101874A (en) Vaccine
BR9711692A (en) Regulated steel promoter
DK0588177T3 (en) Interferon-alpha / beta-binding protein, preparation thereof and pharmaceutical preparations containing the protein
Shieh et al. Regulation of the human IgE receptor (Fc epsilonRII/CD23) by Epstein-Barr virus (EBV): Ku autoantigen binds specifically to an EBV-responsive enhancer of CD23.
TR200002611T2 (en) Beta-lipotropin and its uses
BR0016740A (en) Cryptosporidium sporozoite antigens
DK318086A (en) PREPARATION FOR THE TREATMENT OF HAEMOFILI A INHIBITOR PATIENTS AND PROCEDURE FOR THE PREPARATION OF SUCH PREPARATION

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]